Osaterone

• CAT Number: I033984
• CAS Number: 105149-04-0
• Molecular Formula: C20H25ClO4
• Molecular Weight: 364.867
• Purity: 98%
• Synonyms: Osaterone
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: ( )-6-Chloro-17-hydroxy-2-oxapregna-4,6-diene-3,20-dione
• InChI: InChI=1S/C20H25ClO4/c1-11(22)20(24)7-5-14-12-8-16(21)15-9-17(23)25-10-18(15,2)13(12)4-6-19(14,20)3/h8-9,12-14,24H,4-7,10H2,1-3H3/t12-,13+,14+,18-,19+,20+/m1/s1
• InChIKey: ZLLOIFNEEWYATC-XMUHMHRVSA-N
• SMILES: CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])C=C(Cl)C4=CC(OC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O

Osaterone (Cat No.: I033984) is a steroidal anti-androgen primarily used in veterinary medicine to treat benign prostatic hyperplasia (BPH) in male dogs. It functions by inhibiting the effects of androgens on the prostate, reducing its size and alleviating urinary symptoms. Osaterone competes with dihydrotestosterone (DHT) for androgen receptor binding while also suppressing testosterone synthesis. Unlike other anti-androgens, it has a long-lasting effect with minimal side effects. Its efficacy and safety make it a preferred choice for managing prostate disorders in veterinary practice.

Reference

1: Albouy M, Sanquer A, Maynard L, Eun HM. Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs. Vet Rec. 2008 Aug 9;163(6):179-83. PubMed PMID: 18689779.
2: Tsutsu T, Hori T, Shimizu M, Orima H, Kawakami E, Fukuda S. Regression of prostatic hypertrophy by osaterone acetate in dogs. J Vet Med Sci. 2000 Oct;62(10):1115-9. PubMed PMID: 11073087.
3: Socha P, Zduńczyk S, Tobolski D, Janowski T. The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia. Pol J Vet Sci. 2018 Dec;21(4):559-566. doi: 10.24425/pjvs.2018.125601. PubMed PMID: 30605276.
4: Tsutsui T, Hori T, Shimizu M, Tatsuzawa C, Kawakami E. Effect of osaterone acetate administration on prostatic regression rate, peripheral blood hormone levels and semen quality in dogs with benign prostatic hypertrophy. J Vet Med Sci. 2001 Apr;63(4):453-6. PubMed PMID: 11346183.
5: Niżański W, Levy X, Ochota M, Pasikowska J. Pharmacological treatment for common prostatic conditions in dogs – benign prostatic hyperplasia and prostatitis: an update. Reprod Domest Anim. 2014 Jun;49 Suppl 2:8-15. doi: 10.1111/rda.12297. Review. PubMed PMID: 24947855.
6: Minato K, Koizumi N, Honma S, Tsukamoto K, Iwamura S. Pharmacokinetics and biliary excretion of osaterone acetate, a new steroidal antiandrogen, in dogs. Drug Metab Dispos. 2002 Feb;30(2):167-72. PubMed PMID: 11792686.
7: Minato K, Honma S, Shinohara Y, Hashimoto T. Metabolism of osaterone acetate in dogs and humans. Steroids. 2005 Aug;70(9):563-72. PubMed PMID: 15923016.
8: Fuse H, Fukumoto S, Sone H, Miyata Y, Saito T, Nakayama K, Takahashi H, Matsumoto T, Ogata E. A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats. J Bone Miner Res. 1997 Apr;12(4):590-7. PubMed PMID: 9101370.
9: Minato K, Koizumi N, Honma S, Iwamura S, Tsukamoto K. Characterizations of mouse hepatic microsomal monooxygenase catalyzing 11beta-hydroxylation of osaterone acetate. Biochem Pharmacol. 1999 Jul 15;58(2):335-41. PubMed PMID: 10423176.
10: Barbon AR, Ordóñez IA, Haworth P, Glendewar G, Routh A, Pocknell A. DIAGNOSIS AND MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA IN A PIED TAMARIN (SAGUINUS BICOLOR). J Zoo Wildl Med. 2016 Jun;47(2):609-13. doi: 10.1638/2015-0215.1. PubMed PMID: 27468035.